EUCTR2013-001326-25-ES
Active, Not Recruiting
N/A
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after renal transplantation. - PARIDOINAL2013
Fundación SENEFRO0 sitesJune 10, 2013
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Secondary hyperparathyroidism after renal transplantation
- Sponsor
- Fundación SENEFRO
- Status
- Active, Not Recruiting
- Last Updated
- 10 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.\-Patients that have willingly signed and dated the ICD approved by the EC before any study procedure and after they have been explained the study, they have read the ICD and have had the opportunity to make questions about it.
- •2\.\-Patients of both genders and older than 18 years candidates to an immediately renal transplantation from living or deceased donor.
- •3\.\-24 hours previous to the transplantation patient must have iPTH levels between 250 and 600 pg/mL as per central laboratory results.
- •4\.\-Patients with a preformed antibody panel \<20% 24 hours before the transplantation or that are considered by the investigator of low immunological risk (PRA determination is being done on local laboratory, not central).
- •5\.\-Serum calcium (corrected by albumin) \< 10 mg/dL 24 hour previous to the transplantation as per central laboratory results.
- •6\.\-Patients that are to be treated with immunosupresion based on tacrolimus, mofetil micofenolate or micofenolic acid and with steroids and that are not going to be treated with mTOR inhibitors. Tacrolimus and steroids must not be removed on the 6 month post\-transplantation.
- •7\.\-Patients that are able to take oral capsules on the first week post\-transplantation.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
Exclusion Criteria
- •1\.\-Third or subsequent renal transplantation.
- •2\.\-Positive cross\-match assay or ABO incompatibility
- •3\.\-Patients that have been or are going to be recipients of other organs other than the kidney or a double kidney transplantation.
- •4\.\-Patients with history of allergic reaction or sensibility to paricalcitol, calcifediol or similar study drugs (related with vitamin D).
- •5\.\-Patients with chronic gastrointestinal disease, that, based on investigators criteria, can cause significant gastrointestinal malabsortion.
- •6\.\-Patient with hypo or hyperthyroidism not controlled based on investigators criteria.
- •7\.\-Patient with uncontrolled hypertension based on investigators criteria.
- •8\.\-Patients that, 48 hours previous to transplantation, have been receiving calcimimetics.
- •9\.\-Patients with VIH infection of positive serology for HBV and/or HCV
- •10\.\-Patients on treatment with drugs contraindicated with paricalcitol and calcifediol (based on SMPC)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Terminated
Phase 4
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13
Active, Not Recruiting
N/A
Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5. - PRIMO IIStage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who have Left Ventricular Hypertrophy (LVH)MedDRA version: 14.1Level: LLTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 100000004857MedDRA version: 14.1Level: PTClassification code 10049773Term: Left ventricular hypertrophySystem Organ Class: 10007541 - Cardiac disordersTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2007-005092-33-ITAbbott GmbH & Co. KG220
Completed
Phase 3
Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary HyperparathyroidismSecondary HyperparathyroidismHemodialysisNCT01341782AbbVie (prior sponsor, Abbott)255
Active, Not Recruiting
N/A
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2007-006645-41-NLSint Lucas Andreas Hospital
Recruiting
Phase 4
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.hyperparathyroidismincreased activity of the parathyroids1003394910029149NL-OMON31628Sint Lucas Andreas Ziekenhuis114